Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) and may include paid advertising.

• The importance of real-time decision-making, resilience in GPS-denied environments, and giving drones and other autonomous systems greater independence are driving demand for advanced intelligence technologies.
• A company positioned at the center of this shift is SPARC AI, which develops GPS-independent target acquisition, positioning and autonomous navigation software for drones and other autonomous systems.
• SPARC AI combines proprietary spatial mathematics, machine learning and sensor fusion to provide positioning and target geolocation capabilities designed to support targeting and navigation when GPS is jammed, spoofed or unavailable.

Whether in defense, rescue or commercial applications, there is growing demand for greater intelligence and autonomy in unmanned systems. A major driver is the increasing prevalence of GPS jamming and spoofing, which can compromise navigation and positioning when satellite signals are degraded or unavailable.

The issue is extending beyond the battlefield. CNN recently reported that GPS interference is creating navigation challenges for aircraft operating near conflict zones, while Sky News reported more than one million GPS-jamming incidents in the Middle East Gulf since the start of the Iran war. The disruption has affected everything from drones and ships to passenger aircraft, highlighting the growing vulnerability of GPS-dependent systems.

For autonomous platforms, this creates a need for positioning and navigation capabilities that can remain effective when GPS is unreliable. Beyond resilience, intelligent autonomous systems can also provide low-latency decision-making and reduce dependence on external infrastructure, helping them operate more effectively in challenging environments.

A company focused on addressing these challenges is SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF). SPARC AI develops GPS-independent target acquisition, positioning and autonomous navigation software for drones and other autonomous systems.

SPARC AI’s flagship Overwatch platform is designed to provide positioning, targeting and intelligence capabilities across drone platforms without relying on GPS. The platform brings together capabilities including target acquisition, navigation and positioning into a software-based system designed for contested environments.

Overwatch can process telemetry from drones and other moving platforms and provide positioning information even when GPS is jammed, spoofed or unavailable. The company’s approach is designed to avoid the need for additional specialized hardware such as radar or lidar, helping reduce the weight, cost and power requirements associated with adding new capabilities to a drone.

At the core of SPARC AI’s technology is a combination of proprietary spatial mathematics, machine learning and sensor fusion. These technologies are designed to extract useful positioning and target information from sensor and telemetry data, supporting navigation and target acquisition in environments where conventional GPS-based systems may not be reliable.

SPARC AI has also continued expanding Overwatch beyond individual aircraft. The platform can bring information from multiple drones onto a shared operating picture, allowing operators to classify and track targets, collaborate and plan missions across connected systems. The company has additionally integrated image recognition into its drone controller application, further expanding the platform’s intelligence capabilities.

More recently, the company launched the Overwatch Positioning Network, which moves GPS-independent positioning into a network-based service. Under the model, drones send available telemetry to Overwatch and receive positioning information back, without requiring additional equipment or software to be installed on the aircraft. The company says the service can return positioning in roughly one-third of a second.

This approach could allow GPS-independent positioning capabilities to scale across fleets without requiring operators to equip each individual aircraft with specialized positioning hardware. SPARC AI is initially deploying the network in Ukraine, where GPS-denied conditions are particularly relevant, while also pursuing opportunities across U.S. and allied defense and public-safety markets.

For more information, visit the company’s website at https://sparcai.co.

NOTE TO INVESTORS: The latest news and updates relating to SPAIF are available in the company’s newsroom at https://ibn.fm/SPAIF

• NGTF’s TechForce Robotics is developing a proprietary network designed to coordinate robots, AI systems and smart devices across connected environments.
• The company’s patent-pending decentralized technology is designed to allow connected machines to negotiate and reassign tasks based on real-time operating conditions, reducing the need for constant human intervention.
• TechForce is applying its automation platform across hospitality, commercial and industrial markets, with a recent NBR Intelligence framework contemplating a nonbinding planning target of up to 5,000 robotic systems.

As robotics adoption accelerates, the challenge is shifting from building individual machines to making increasingly diverse robotic fleets work together. A cleaning robot, delivery robot, industrial arm and laboratory system may each perform its assigned task autonomously, but coordinating those machines across a facility can still require significant human oversight.

That creates an opportunity for the software and connectivity layer sitting between individual machines.

Nightfood Holdings (OTCQB: NGTF), operating through its TechForce Robotics brand, is developing technology around that opportunity. The company’s Robotic Connective Network is designed to allow AI systems, robots, sensors and smart devices to exchange information and coordinate workflows within a common operational environment.

The broader robotics market is already moving toward greater commercial adoption. The International Federation of Robotics reported nearly 200,000 professional service robots sold worldwide in 2024, up 9% year over year, while transportation and logistics robots reached 102,900 units. Robotics-as-a-Service fleets also grew 31%, reflecting increasing demand for automation delivered through recurring service models.

As more robots enter real-world facilities, interoperability and coordination become increasingly important.

Building a Coordination Layer

TechForce’s Robotic Connective Network is designed to address that challenge by creating a common communication and coordination layer between connected machines. Rather than simply allowing different robots to operate alongside one another, the system is intended to help them coordinate workflows and respond to changing conditions.

At the core of the platform is TechForce’s patent-pending decentralized coordination technology. The system is designed to allow connected devices to negotiate task ownership based on factors such as workload, proximity, battery capacity and operating conditions.

That distinction matters because individual robot autonomy does not necessarily create fleet-level autonomy. A robot can independently complete a task while still requiring a human operator to determine what happens next. As fleets grow, that manual coordination can become an operational bottleneck.

TechForce’s approach is intended to address that gap. If one machine completes an assignment, the network could help determine which available robot is best positioned to take on the next task. Likewise, if a machine is approaching low battery or encounters another operating constraint, work could potentially be reassigned to a more suitable unit.

Moving From Technology to Deployment

The opportunity becomes more tangible as TechForce expands its focus beyond hospitality and commercial service robotics into industrial environments.

On August 17, an AINewsWire editorial highlighted TechForce’s recently announced letter of intent with Singapore-based NBR Intelligence Pte. Ltd., which contemplates a nonbinding planning target of up to 5,000 robotic systems for factory automation. The framework begins with five pilot units, with operational, safety, network and workflow assessments preceding any larger deployment.

The proposed program is structured around measurable performance criteria, including availability, task completion, throughput, accuracy and safety. The contemplated robotic mix includes 4- to 6-axis robotic arms alongside TechForce’s LIM-E and Kebb-i platforms, with the company’s targeting automation of up to 30% of identified workflows at participating sites.

The staged approach is significant because industrial robotics requires more than technical capability. Systems must operate reliably within existing facilities, integrate with workflows and demonstrate measurable performance before operators can justify broader deployment.

TechForce’s RaaS model is also designed to lower that adoption barrier. Instead of requiring customers to make a large upfront capital investment, RaaS can shift robotics toward an ongoing operating expense while creating opportunities for recurring service relationships. Industry data indicates that this model is gaining traction, with RaaS fleets growing 31% in 2024.

Expanding Across Automation Markets

The NBR framework is part of a broader expansion for TechForce. The company has been extending its platform beyond hospitality into pharmaceutical, laboratory, semiconductor and industrial automation.

In June, TechForce completed the initial deployment of its LIM-E autonomous laboratory support robot as part of its pharmaceutical automation initiative with Oncotelic Therapeutics. A subsequent phase involved deployment of its PUR-E clean-room support robot at a sterile injectable cGMP facility, expanding the company’s exposure to regulated pharmaceutical manufacturing environments.

TechForce has also established a strategic relationship with Taiwan-based Jiun Jiang Enterprise, targeting semiconductors, advanced packaging, precision automation and industrial manufacturing applications. The companies are evaluating potential additional manufacturing capacity in Taiwan and the United States as demand develops across these markets.

That diversification could make the coordination layer increasingly relevant. Different industries may require different machines and workflows, but the underlying challenge remains similar: connecting autonomous systems so they can operate efficiently within a larger environment.

The Opportunity Beyond the Robot

For investors, the larger opportunity may therefore extend beyond individual robotic systems.

TechForce is building a platform that combines robotics, AI-enhanced software, real-world deployments and a coordination layer designed to connect machines across operational environments. If the technology can support third-party systems as intended, the addressable opportunity could extend beyond robots manufactured or deployed directly by TechForce.

The distinction is becoming increasingly important as the robotics industry moves from isolated demonstrations toward real-world deployment. Industrial installations reached 542,000 units globally in 2024, while labor shortages continue pushing operators toward automation.

The next phase of robotics may consequently depend not only on how capable individual machines become, but on how effectively those machines can work together.

TechForce Robotics is positioning its Robotic Connective Network around that challenge while simultaneously expanding into the commercial and industrial environments where coordinated automation could have its greatest impact. If the company can translate its technology into repeatable deployments, the coordination layer could become an increasingly important component of its broader robotics and automation platform.

For more information, visit the company’s website at TechForceRobotics.com.

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at http://ibn.fm/NGTF

• The company began trading on the OTCQB Venture Market on August 21, completing its transition from the OTCID market.
• The move follows the completion of the FINRA Form 211 process, allowing proprietary broker-dealer quotations in AMFN and potentially broadening market participation.
• The company reported 100 patent applications pending after filing 17 additional U.S. applications covering components and configurations of its Texatron(TM) Fusion Engine(TM) platform.
• American Fusion(TM) has moved the Texatron(TM) program from engineering preparation into active testing, including work at Texas Tech University and continued evaluation of its 500 kW and 5 MW configurations.
• The company is holding preliminary discussions concerning potential power offtake arrangements and Power Purchase Agreements, although no definitive agreements have been signed.

American Fusion(TM) (OTCBQ: AMFN), a developer of next-generation fusion energy technologies, has entered a new phase of its public-market development, with the company beginning trading on the OTCQB Venture Market while simultaneously expanding the intellectual-property portfolio surrounding its Texatron(TM) Fusion Engine(TM).

The OTC move became effective August 21 under the company’s existing ticker, AMFN, after OTC Markets Group approved the upgrade and FINRA processed a Form 211 submitted by Alpine Securities, the company’s sponsoring market maker. American Fusion(TM) had previously traded on the OTCID market (https://ibn.fm/VObmL).

The change is primarily a market-structure development rather than a technology milestone. But for an early-stage energy company seeking capital to fund engineering and commercialization, the distinction matters. Completion of the Form 211 process means proprietary bid and ask quotations can be published in AMFN, rather than the stock being limited to an unsolicited-quotation environment. OTCQB companies are also required to maintain current reporting and satisfy ongoing market and corporate requirements.

American Fusion(TM) became an SEC-reporting company in May after its Form 10 registration statement became effective. Management has described OTCQB as an intermediate stage in a broader capital-markets strategy that could eventually include an application to a national securities exchange. The company has identified the Nasdaq Capital Market and Texas Stock Exchange as potential venues, although no listing has been approved or guaranteed.

The capital-markets development comes as the underlying technology program reaches a more consequential stage.

American Fusion(TM), through its wholly owned Kepler Fusion Technologies business, is developing the Texatron(TM) Fusion Engine(TM) as a modular fusion-energy platform. The company is pursuing an approach based on pulsed electromagnetic compression and has described the platform as intended for aneutronic fusion using deuterium and helium-3.

The central question for investors is no longer simply whether American Fusion(TM) has a conceptual design. It is whether the company can demonstrate the relevant plasma conditions and system performance through controlled testing. That process is underway.

American Fusion(TM) began testing at Texas Tech University in late July, following receipt of a Texas Department of State Health Services certificate covering its registered Texatron(TM) research systems. The initial phase included engineering evaluations, subsystem demonstrations, instrumentation testing and laboratory activities. The company subsequently reported completion of that initial phase.

The company has also continued testing work since then. Its Aug. 27 update said experiments involving 500 kW and 5 MW Texatron(TM) configurations were being used to evaluate progress toward the plasma conditions required for deuterium-helium-3 fusion. American Fusion(TM) also said a new portable vacuum chamber had arrived to support the continuing experimental program.

The company has been explicit that substantial scientific and engineering work remains before it can demonstrate ignition or net energy gain. That qualification is important because testing a fusion device and demonstrating commercially relevant net energy are very different milestones.

The 5 MW pre-production Texatron(TM) is central to the current program. American Fusion(TM) took delivery of the system in June after completing fabrication and modifications, moving the project from prototype development toward installation, commissioning and integrated testing.

Regulatory preparation has advanced alongside the engineering work. The Texas DSHS certificate issued in July covers 12 registered Texatron(TM) model classes ranging from 500 kW to 1 GW for research and development activities, subject to the conditions of the registration.

Meanwhile, the company has continued to expand its intellectual property. On August 24, American Fusion(TM) announced that it had reached a key milestone of 100 pending patent applications after filing 17 additional U.S. applications (https://ibn.fm/zNXIN). The new filings address areas including aluminum fusion-confinement structures, rifled toroidal chambers, electromagnetic-field structures, fuel-injection systems and coil configurations.

The distinction between pending applications and granted patents is important. The filings do not establish that the inventions will ultimately receive patent protection, nor do they demonstrate that the underlying technology is commercially viable. They do, however, show that American Fusion(TM) is attempting to protect the Texatron(TM) concept across multiple configurations rather than treating the technology as a single reactor design.

American Fusion(TM) is also beginning to address the other side of commercialization: potential customers. The company says it is engaged in preliminary discussions regarding prospective electricity offtake arrangements and Power Purchase Agreements for future Texatron(TM)-generated power. No definitive agreements have been executed, and any such arrangements would depend on successful testing, commercialization, regulatory requirements and financing.

The potential customer base is broad. American Fusion has discussed applications involving data centers, industrial facilities, defense and other infrastructure where reliable electricity could be valuable. The company’s July commercialization update highlighted discussions with potential counterparties as testing advanced.

American Fusion(TM) also said it intends to continue using equity financing rather than convertible debt and currently reports no convertible notes outstanding. It is also evaluating a potential Frankfurt quotation or listing to expand its access to European investors, although that initiative remains subject to eligibility and regulatory requirements.

“We have financed the company through equity, funded our operating requirements without relying on convertible debt, continued advancing the Texatron(TM), and built the corporate infrastructure necessary to reach this point,” said CEO Richard Hawkins. “OTCQB is an important milestone, but it is also part of a much larger plan to position American Fusion for the capital markets and commercial opportunities ahead.”

For more information, visit the company’s website at www.AmericanFusionEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to AMFN are available in the company’s newsroom at https://ibn.fm/AMFN

• Silynx’s in-ear tactical communication system amplifies drone-related frequencies, allowing the operator to hear an approaching drone sooner, a capability the company first brought to market in 2024.
• Silynx is developing an in-ear headset being built into the company’s existing platform, requiring no additional worn devices, and designed to transmit vital life signs alerts to commanders and command centers even when the user is incapacitated.
• Silynx’s long-standing supplier relationships reflect a sustained track record with demanding customers, and capabilities like drone detection are how the company continues to earn that position.

Whether you’re in the military, law enforcement, riot control, or other loud, chaotic, and potentially-dangerous industries, the ability to communicate with your team effectively, while also protecting your hearing, is critical. To address this growing need, Silynxcom Ltd. (NYSE American: SYNX) has developed exceptional in-ear tactical communication systems.

Silynx offers these products to hundreds of customers across more than 40 countries, supporting professionals over a range of industries, to protect user hearing without compromising communication or hurting situational awareness.

The company’s products are valued by elite US and international warfighters to protect hearing, boost environmental awareness, and improve communication, without adding unnecessary weight or affecting helmet fit.

Silynx’s Drone Detection, which is an advanced audio enhancement mode that’s designed to let users hear distant drone activity sooner, allowing more time to react. When the mode is activated, the system amplifies the specific frequency ranges produced by drone motors and rotors, which help these sounds stand out from the rest of the environment. This allows for much better awareness and readiness during patrols, perimeter security, recon, and other operations.

In addition, the company’s CLARUS II offers pre-recorded voice messages, and a whisper mode for near-silent transmissions. (Pre-recorded messages are a function Silynx develops for Special Forces requirements for CQB environments.)

Silynx is currently developing an in-ear headset being built into the existing platform, designed to provide real-time vital life signs monitoring, transmitting alerts to commanders and command centers even when the user is incapacitated. 

These unique functions, as well as others, including the fact that their products are rated up to NRR 31 dB, among the highest available ratings for in-ear tactical hearing protection, have helped Silynx become a long-term supplier for several key customers, in one case for over three decades. 

About Silynxcom Ltd. (NYSE American: SYNX)

Silynx is a developer of rugged tactical communication headsets designed to improve awareness, boost communication efforts, and enhance hearing in loud, chaotic, and dangerous environments. Silynx systems are used across different industries including military, law enforcement, shooting sport, industrial, and a riot control. The systems have wide compatibility and are built using multiple cutting-edge and proprietary technologies.

For more information, visit Silynx’s website at https://silynxcom.com.

NOTE TO INVESTORS: The latest news and updates relating to SYNX are available in the company’s newsroom at https://ibn.fm/SYNX

• Music preservation is not a hypothetical problem, and digital distribution further complicates the issue.
• Through its subsidiary Melody Trust, HWAL holds rights to master recordings from an array of artists.
• HWAL has reached beyond simple licensing to new artist development.

Streaming apps shuffle through millions of songs in seconds, yet almost nobody asks who is actually protecting the original master recordings once the algorithm moves on. HWAL (OTC: HWAL) is a holding company built around that exact question.

Through its subsidiary Melody Trust and “Lunar Records”, a jointly held company with SI Blue Foundation (Space Blue), the company curates, licenses and preserves a catalog of music history that spans generations.

Music preservation is not a hypothetical problem. In 2008, a fire at Universal Studios Hollywood destroyed somewhere between 120,000 and 175,000 master recordings, an event later described as one of the worst disasters in music industry history. The loss went largely unreported to the public for more than a decade.

Physical vaults are not the only vulnerability facing older recordings. Ownership records for catalogs from earlier decades are often scattered across defunct labels, artist estates and layered licensing agreements. That fragmentation makes it difficult for royalties to reliably reach the performers and songwriters who created the work in the first place.

Digital distribution has also reshaped how a catalog generates value. Music rights are increasingly treated as intellectual property that can be licensed across streaming, film, television, and gaming platforms, rather than simply pressed onto vinyl or tape and left in a warehouse.

Stepping into that space is HWAL Inc., formerly known as Hollywall Entertainment, which describes itself as a multimedia holding company focused on entertainment, real world assets and digital media. Headquartered in the United States, the company trades publicly under the ticker HWAL.

The company’s entertainment focus centers on a catalog of master recordings. HWAL holds rights connected to recordings from artists including Ray Charles, Aretha Franklin, Elvis Presley, Dolly Parton, James Brown, the Jackson 5 and thousands more. To manage those assets, the company formed the subsidiary Melody Trust LLC, which protects and safeguards royalty interests held by the performers and composers behind its catalog.

HWAL has also moved into tokenized real-world assets. Earlier this year, Lunar Records formed Lunar Records Fund 1, a blockchain-based structure to let investors share directly in royalties generated by its music assets. Based on its calculations, the company reports that its music catalog and related intellectual property were assessed by an independent valuation firm at roughly $480 million as of its most recent quarterly disclosure.

Melody Trust has since looked beyond traditional licensing to grow that catalog’s reach. In October 2025, it entered a joint venture with SI Blue Foundation, (SpaceBlue). Called Lunar Records, the collaboration aims at pairing the existing catalog with new artist development, merchandising, licensing and distribution models. That partnership connects HWAL to the broader entertainment industries.

On February 22, 2024, the Odysseus lander touched down near the Moon’s South Pole, marking the first American spacecraft to soft-land on the lunar surface in more than 50 years. The mission was part of NASA’s Commercial Lunar Payload Services initiative.

Attached to that lander was the Lunaprise Museum, as the first art and music museum confirmed by NASA as a lunar payload. The museum holds 222 art projects and 777 songs stored on a multilayer disc system designed to remain intact for more than a billion years. Space Blue, the company behind that lunar payload, is now HWAL’s partner in Lunar Records. That relationship extends the reach of HWAL’s catalog from vaults on Earth to an archive placed permanently on the Moon as reported in Billboard magazine.

HWAL’s approach stands out for how far it reaches: a catalog of master recordings, paired with blockchain-based royalty tools. Few holding companies are working across that many frontiers at once, and fewer still are doing it with a catalog as deep as HWAL’s. That combination of legacy and innovation gives the company a distinctive position from which to build out its next chapter.

For more information, visit www.HWAL.net.

NOTE TO INVESTORS: The latest news and updates relating to HWAL are available in the company’s newsroom at https://ibn.fm/HWAL

Disseminated on behalf of Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) and may include paid advertising.

• Powermax has a portfolio of rare earth element projects across Canada and the United States, positioning itself within a market increasingly tied to energy and national security.
• Projects include Atikokan and Pinard in Ontario, Cameron in British Columbia, and Ogden Bear Lodge in Wyoming, with 2026 exploration work focused on converting geophysical and geochemical anomalies into prioritized targets for follow-up exploration.
• Demand for magnetic rare earth elements is projected to rise sharply, with McKinsey estimating growth from 59,000 tonnes in 2022 to 176,000 tonnes by 2035.
• Neodymium, praseodymium, dysprosium and terbium are particularly important because of their role in high-performance permanent magnets used across commercial and defense technologies.
• U.S. restrictions taking effect in 2027 will extend procurement rules for certain rare-earth magnets across production, adding urgency to efforts to develop alternative supply chains.

Powermax Minerals (CSE: PMAX) (OTCQB: PWMXF), a Canadian mineral exploration company, is building its portfolio around a commodity whose importance increasingly extends beyond the traditional mining and energy sectors: rare earth elements (“REEs”). The company has exposure to four REE projects across Canada and the United States, with exploration advancing at several properties. The portfolio includes the Atikokan and Pinard properties in Ontario, the Cameron project in British Columbia and the Ogden Bear Lodge project in Wyoming.

The investment case for early-stage REE exploration is connected to the applications these elements support. Rare earths are used in permanent magnets, catalysts, electronics, and other advanced technologies for both commercial and defense application. Among the 17 elements classified as rare earths, neodymium, praseodymium, dysprosium and terbium are particularly important to high-performance magnet production. McKinsey estimates that magnetic REEs currently account for about 30% of total REE volume but more than 80% of the industry’s value.

The demand outlook is substantial and continues to grow. McKinsey projects global demand for magnetic rare earths to increase from approximately 59,000 tonnes in 2022 to 176,000 tonnes by 2035. Electric vehicles and wind-power expansion are among the principal drivers, while the supply pipeline could fall short of projected demand by roughly 60,000 tonnes in 2035 under its analyzed scenario.

Although commercial demand is dominant, it is only one part of the equation. Rare earth magnets are also embedded in military systems where high magnetic strength and heat resistance are critical. In today’s conflict-oriented geopolitical environment, weapons development and stockpiles are under growing pressure. The U.S. Department of Defense identifies permanent rare earth magnets as essential components in platforms including F-35 aircraft, Virginia- and Columbia-class submarines, unmanned aerial vehicles, missiles and radar systems (https://ibn.fm/bqSmM).

The Pentagon says an F-35 requires more than 900 pounds of rare earth elements, while an Arleigh Burke-class destroyer requires about 5,200 pounds and a Virginia-class submarine approximately 9,200 pounds.

The same magnetic properties that make neodymium and related elements valuable in electric motors and wind turbines also make them important for military propulsion, actuators, guidance systems and other applications. The Department of Energy similarly identifies rare earths as important to national security, energy independence and technologies spanning transportation and power generation.

This has turned supply security into a policy issue. China remains dominant across significant portions of the global rare earth supply chain. The U.S. Government Accountability Office has noted that China mines nearly 70% of global rare earth supply and controls important processing capacity, while the Pentagon has described overseas concentration as a vulnerability for defense supply chains.

Washington has consequently been directing capital toward alternative supply. The Department of Defense said in 2024 that it had awarded more than $439 million since 2020 to establish domestic rare earth supply chains, including separation, refining, metallization and magnet production. The objective is a domestic “mine-to-magnet” chain capable of supporting U.S. defense requirements.

The regulatory framework is also changing. Under DFARS 225.7018, restrictions on covered rare-earth materials are scheduled to broaden on January 1, 2027. For neodymium-iron-boron magnets, for example, the restriction will extend to the supply chain from mining of neodymium, iron and boron through production of finished magnets when the relevant materials originate in designated covered countries.

That backdrop helps explain why North American exploration projects can attract attention even before a discovery reaches an economic-development stage. Powermax remains in the exploration phase, and its current objective is to identify and advance targets rather than claim established commercial production.

Atikokan illustrates the approach. Powermax reported in January that interpretation of helicopter-borne magnetic and radiometric survey data had identified multiple structurally controlled REE exploration targets across the property’s claim blocks. The company said the targets showed relationships among granitic and pegmatitic rocks, radiometric signatures and previously identified lake-sediment anomalies.

At Cameron in British Columbia, earlier 2026 soil and surface-rock sampling produced Total Rare Earth Oxide values ranging from approximately 135 parts per million to 2,840 ppm, with several anomalous samples. Powermax described the results as defining priority targets for follow-up exploration.

The company also commenced airborne geophysical surveys and field programs at Pinard and Hopkins in Ontario in June. At Pinard, the planned survey covers approximately 1,319 line-kilometres and is designed to help identify geological structures, alteration patterns and radiometric anomalies that could guide further REE exploration.

Ogden Bear Lodge adds a U.S. dimension to the portfolio. Powermax owns 100% of the Wyoming project, giving the company exposure to a U.S. jurisdiction at a time when Washington is actively seeking to reduce dependence on foreign critical-mineral supply chains.

For more information, visit the company’s website at www.PowermaxMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to PWMXF are available in the company’s newsroom at https://ibn.fm/PWMXF

• Earth Science Tech recently completed the acquisition of Zoolzy LLC, a wholesale distributor of active pharmaceutical ingredients (“APIs”) and finished FDA-approved prescription products
• The acquisition delivers value across three growth drivers, including expanding overall profit margins, broadening access to new ingredients, and enabling entry into the veterinary market
• The acquisition represents Earth Science Tech’s move to seize strategic opportunities that broaden the company’s telehealth and pharmacy fulfillment platforms into new, complementary verticals

Earth Science Tech (OTC: ETST), a strategic holding company in the healthcare, pharmacy, and telemedicine sector, recently acquired Zoolzy LLC. Based in Doral, Florida, where it operates from a 3,684-square-foot facility, Zoolzy is a wholesale distributor of active pharmaceutical ingredients (“APIs”) and finished FDA-approved prescription products (https://ibn.fm/vcqkE).

The acquisition complements and supports ETST’s compounding pharmacies by enabling them to secure essential raw materials at highly competitive wholesale pricing, significantly increasing the company’s overall profit margins. It also expands ETST’s supply network, broadening access to novel, highly sought-after APIs to increase its custom compounding capabilities. 

Additionally, the acquisition gives Earth Science Tech immediate, strategic procurement access to common veterinary medications, enabling the company to expand into the animal health market. Through this new, high-margin vertical, ETST will focus on formulating unique, flavored, and easy-to-administer veterinary therapeutics.

The highly accretive acquisition of Zoolzy is the latest in Earth Science Tech’s strategic investments to catalyze immediate growth and deliver financial and operational value to shareholders. It follows the acquisition of La Verne, California-based Meduvo LLC, a compounding pharmacy whose addition to ETST’s fold established a highly strategic West Coast operational hub and expanded its network to 34 U.S. jurisdictions (https://ibn.fm/ChJUS).

“Looking ahead, we are focused on scaling the business by expanding our geographic footprint, advancing our telehealth and pharmacy fulfillment platforms, and building long-term, sustainable shareholder value,” committed Giorgio R. Saumat, CEO and Chairman of the Board, during the release of the company’s fiscal first quarter 2027 financial results (https://ibn.fm/2BOyR).

The results continued trend from fiscal 2026, in which all key operating subsidiaries achieved profitability. Still, the company said management remains focused on actively evaluating strategic opportunities to broaden its telehealth and pharmacy fulfillment platforms into new, complementary verticals. The completion of the Zoolzy acquisition, therefore, reflects the Earth Science Tech’s execution of its management’s commitment.

For more information, visit the company’s website at www.EarthScienceTech.com.

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST

Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising.

• Gold has demonstrated remarkable resilience despite periodic pressure from higher bond yields, while central-bank buying, geopolitical uncertainty and concerns surrounding currencies and sovereign debt continue supporting demand for the precious metal.
• China’s move to restrict certain retail paper-gold products could further reshape investor demand, although the long-term impact on physical gold remains uncertain.
• For Lahontan Gold, a sustained gold market could provide an important backdrop as the company advances its flagship Santa Fe Mine toward a potential return to production in 2027 following a 22% increase in its mineral resource estimate.

Gold’s relationship with interest rates has long been one of the most closely watched dynamics in precious-metals markets. Because gold does not generate interest or dividends, higher real yields can increase the opportunity cost of holding the metal and, under traditional market conditions, create a headwind for prices.

Yet gold has demonstrated considerable resilience in 2026, with prices recently climbing to multi-month highs despite periods of elevated Treasury yields. The market’s strength suggests that other forces, including central-bank demand, geopolitical uncertainty, fiscal concerns and investor demand for hard assets, are increasingly influencing the precious metal’s trajectory.

Central-bank buying has become an especially important part of the story. According to the World Gold Council, central banks purchased 289 tonnes of gold during the second quarter of 2026, while China’s central bank added another 20 tonnes in July. Chinese gold ETFs also continued to see inflows during July and into August.

At the retail level, China’s gold market is also undergoing a significant shift. Several major Chinese banks have moved to end certain retail paper-gold trading products linked to the Shanghai Gold Exchange, with customers encouraged to close positions, sell or take physical delivery.

The change does not guarantee a surge in physical-gold demand, and the July transition did not immediately produce a major price shock. However, it could alter how some retail investors gain exposure to gold and potentially reinforce demand for physical bullion over time.

For gold developers and explorers, the implications of a structurally stronger precious-metals market can extend beyond the commodity price itself. Higher gold prices can improve the potential economics of deposits, increase investor attention toward development-stage projects and provide companies with greater flexibility as they advance toward production.

One company positioned within this environment is Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF), a dual-listed Canadian/U.S. mine development and exploration company advancing four gold and silver projects across the prolific Walker Lane region.

At the center of the company’s strategy is the Santa Fe Mine, a past-producing open-pit, heap-leach gold-silver operation in Mineral County, Nevada. The project benefits from existing mining and processing infrastructure and a history of production, with the company now working to advance the asset toward a potential restart.

Importantly, Lahontan’s Santa Fe story has continued to expand alongside its development efforts. The company recently announced a 22% increase in the project’s Mineral Resource Estimate, with the updated resource totaling approximately 1.195 million ounces of gold equivalent in the Indicated category and 1.190 million ounces in the Inferred category, according to the August 17 announcement. The updated estimate incorporates results from 1,275 drill holes totaling more than 136,000 meters.

The resource growth provides additional scale to a project that Lahontan is simultaneously advancing through permitting, exploration, metallurgical optimization and economic work. The company’s 2026 objectives include completing an updated Mineral Resource Estimate and Preliminary Economic Assessment while continuing mine permitting activities with the goal of commencing construction in 2027.

Exploration is also providing potential avenues for further growth. Recent drilling at Santa Fe has continued to test and expand shallow oxide gold mineralization, including results from the Calvada and other target areas. In August, Lahontan reported a 12.2-meter interval grading 1.25 g/t gold at Calvada East, adding another data point to the company’s ongoing resource expansion efforts.

Beyond Santa Fe, Lahontan is advancing the West Santa Fe project, located approximately 15 kilometers west of its flagship operation. The company is conducting additional drilling there to expand and define an oxidized gold-silver system that could potentially serve as a satellite resource to Santa Fe. Lahontan’s modeling of historical drilling has indicated the potential for a substantial near-surface mineralized system, although additional exploration is required to establish a formal resource.

The combination of a potentially supportive gold market and continued project advancement creates an interesting backdrop for Lahontan. While commodity prices remain inherently cyclical and the company’s path to production still depends on permitting, economic studies, financing and successful development, Santa Fe’s expanding resource base and existing infrastructure provide a foundation from which the company is seeking to advance the project.

If gold demand remains elevated as central banks continue accumulating the metal, investors remain concerned about fiscal and geopolitical risks, and markets continue to reassess the role of hard assets, development-stage companies with sizeable resources could attract increasing attention. For Lahontan, the opportunity is to translate the growing Santa Fe resource and ongoing development work into a potential return to production, with 2027 currently serving as a key target on that path.

For more information, visit the company’s website at www.LahontanGoldCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to LGCXF are available in the company’s newsroom at ibn.fm/LGCXF

• SS Innovation’s SSi Mantra system was used in more than 50 robotic surgeries in a single day at Mohak Bariatrics and Robotics in Indore, highlighting growing clinical utilization in India.
• The milestone comes as SS Innovations reports 224 SSi Mantra systems installed across 12 countries, providing a growing installed base for future procedure and instrument revenue.
• Second-quarter 2026 installations reached 30 systems, above the 25 systems modeled by the analyst cited in the supplied report.
• Quarterly revenue reached $13.9 million, up 39% year over year, while system sales increased 41% to $12.4 million.
• FDA review of the SSi Mantra 510(k) application is now expected by the end of the first quarter of 2027, while European CE marking remains targeted for the end of 2026.
• The company’s progress in India gives it a major commercial base while it pursues entry into the U.S. and European surgical robotics markets.

SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, is gaining another indication of the scale that its SSi Mantra surgical robotic system can support in India, where more than 50 robotic procedures were performed in a single day at Mohak Bariatrics and Robotics in Indore.

The milestone, announced by SS Innovations on LinkedIn, came on India’s 80th Independence Day and involved procedures conducted under the leadership of Dr. Mohit Bhandari. The event is notable less for the headline number than for what it demonstrates about the potential utilization of robotic surgery in a large healthcare market where adoption is still developing (https://ibn.fm/hUbni).

For SS Innovations, India is already the most important commercial market for the SSi Mantra. The company has spent roughly three years building an installed base there, creating a foundation from which procedure volumes and recurring sales of instruments and other consumables can grow. The latest operating figures suggest that this strategy is gaining traction.

According to an analysis by Lucid Capital Markets, SS Innovations placed 30 SSi Mantra systems during the second quarter of 2026, exceeding the analyst’s expectation of 25. Cumulative installations reached 224 systems across 12 countries, representing a substantial increase from the 194 systems reported at the end of the first quarter. First-half installations reached 56 systems, compared with 38 in the first half of 2025 (https://ibn.fm/CCO32).

The corresponding financial performance also reflected the increase in system placements. Second-quarter revenue reached $13.9 million, up 39% from a year earlier, while system sales rose 41% to $12.4 million. Gross margin was 50.9%.

More important for the longer-term economics of a surgical robotics business, utilization is increasing alongside the installed base. The company reported 2,528 robotic surgeries during the quarter, a 143% year-over-year increase. Cumulative procedures performed using SSi Mantra reached 12,272, including 637 cardiac and 222 pediatric cases.

The 50-plus procedure day in Indore therefore fits into a broader pattern: hospitals that have adopted robotic systems are beginning to use them at increasingly high volumes. That matters because surgical robotics economics do not end with the sale of the capital equipment. Once a robotic system is installed, procedures can generate recurring demand for instruments and related products. Higher utilization can therefore increase the economic value of an installed system over its lifetime.

India offers SS Innovations an unusually large market in which to establish that model. The country has a large and increasingly sophisticated private healthcare sector, while demand for advanced surgical procedures continues to expand. Robotic surgery can also address geographic disparities in access to specialist expertise, particularly as SS Innovations develops its telesurgery capabilities.

The company has already demonstrated that its platform can support procedures performed over long distances. During the second quarter and early third quarter, SS Innovations reported telesurgery demonstrations connecting surgeons and patients across thousands of miles, including a robotic cardiac procedure between Guyana and India. This was later followed by an even longer world record telesurgery between Colombia and India.

Telesurgery remains an emerging application rather than the company’s principal source of revenue. The more immediate commercial opportunity is the deployment of SSi Mantra systems and the development of procedure volumes around them. The system itself is designed as a multi-arm robotic platform, with five independently controlled robotic arms and an open-console, high-definition stereoscopic interface. Its modular architecture is intended to support multiple surgical specialties.

That breadth is important when considering the company’s positioning. Affordability is part of the proposition, particularly in markets where the capital cost of robotic systems can constrain adoption. But SS Innovations is attempting to compete on the capabilities of the platform itself rather than simply presenting SSi Mantra as a lower-cost substitute.

The next major test is international regulatory expansion. SS Innovations has submitted its SSi Mantra 510(k) application to the U.S. Food and Drug Administration and is pursuing CE marking for the European Union. The company now expects completion of the FDA review by the end of the first quarter of 2027, one quarter later than previously anticipated. The CE-marking target remains the end of 2026.

U.S. and European approvals could materially expand the addressable market for SSi Mantra. Until then, India’s installed base provides SS Innovations with an opportunity to continue building clinical experience and refining its commercial infrastructure. Training is becoming an important part of that strategy. The company has established the SS International Centre for Robotic Surgery and graduated its first robotic cardiac training class in June. A larger pool of trained surgeons can support higher utilization and potentially make future system placements easier.

The company’s financial position remains a consideration for investors. The second-quarter report cited cash of $13.6 million, excluding restricted cash, and an operating cash burn of $6.5 million during the first half of 2026. Long-term debt was reported at zero, although the company had a $14.6 million bank revolving facility.

“The Q2 results reconfirm that SSII can disrupt the surgical robotics market and create an excellent business in emerging markets while awaiting U.S./EU approval, and we reiterate BUY rating, $7 price target,” the Lucid Capital Markets report states.

For more information, visit the company’s website at www.SSInnovations.com.

NOTE TO INVESTORS: The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII

• VERAXA Biotech and Secarna Pharmaceuticals have reported an initial in vitro proof of concept for an antibody oligonucleotide conjugate (“AOC”) developed through their research alliance.
• The AOC candidate demonstrated greater potency than the equivalent unconjugated oligonucleotide in early testing, providing a first experimental validation of the collaboration.
• AOCs are an emerging class of antibody-guided therapies designed to use an antibody to deliver therapeutic oligonucleotides selectively to disease-relevant cells.
• VERAXA contributes antibody conjugation expertise and proprietary click chemistry, allowing it to participate in AOCs without shifting its core oncology strategy.
• The collaboration adds to VERAXA’s growing partnering track record, which also includes its bispecific ADC discovery alliance with OmniAb.

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, and Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, have reached an early research milestone in their collaboration to develop antibody oligonucleotide conjugates (“AOCs”), providing VERAXA with an initial proof point for applying its conjugation technology outside oncology (https://ibn.fm/mgy0y).

The companies announced on August 24 that an AOC candidate generated by combining their respective technologies demonstrated greater potency in an in vitro study than the equivalent unconjugated, or “naked,” oligonucleotide. The companies are now discussing the next steps for the alliance, which is aimed at potential treatments for autoimmune and chronic immune diseases.

AOCs represent a relatively new category of antibody-guided therapeutics. The basic concept combines the targeting specificity of an antibody with an oligonucleotide payload, such as an antisense oligonucleotide or small interfering RNA. The antibody acts as the targeting component, with the objective of bringing the therapeutic nucleic acid to cells expressing the relevant target.

That approach is being investigated as a way to address some of the limitations associated with systemic delivery of oligonucleotide medicines, including cellular uptake, biodistribution and potential off-target exposure.

The Secarna collaboration therefore places VERAXA at the intersection of two technology areas without requiring the company to build an entirely new therapeutic franchise internally.

Secarna brings its OligoCreator platform and expertise in oligonucleotide discovery. VERAXA contributes its antibody engineering, conjugation and click-chemistry capabilities. The original agreement, announced in September 2025, specifically contemplated using VERAXA’s click-chemistry platform to design and generate AOCs.

VERAXA’s primary development strategy remains oncology. Its principal programs are centered on BiTAC, or Bi-targeted Tumor-Associated Cytotoxicity, a platform designed to create conditionally active antibody therapeutics through dual-target recognition. Its BiTAC technology is being applied to both T-cell engagers and antibody-drug conjugates. The company is advancing its lead BiTAC-TCE program toward IND/CTA-enabling work, while its BiTAC-ADC platform has generated initial in vitro proof-of-concept data.

The company has pursued a similar partnership model in oncology. In May 2025, VERAXA entered a co-discovery alliance with OmniAb to develop a bispecific ADC for solid tumors. OmniAb contributed antibody discovery and screening capabilities, while VERAXA provided ADC linker technology and conjugation expertise. In July, VERAXA announced that the discovery phase had been completed and that the resulting VXA-222 program had advanced into its next phase, with VERAXA taking responsibility for establishing the lead candidate and conducting subsequent validation.

That progression provides useful context for the Secarna relationship. The partnerships are directed at different therapeutic areas, but they employ a similar strategic principle: combine VERAXA’s specialized antibody and conjugation capabilities with complementary technologies from outside partners.

The company has also been building intellectual-property protection around these capabilities. In July, VERAXA reported more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries. Its patent portfolio includes technologies covering conjugation and click chemistry in addition to its BiTAC-TCE and BiTAC-ADC platforms.

VERAXA describes its click chemistry as a platform for producing efficient and stable antibody-payload conjugates, with the potential to control conjugation and generate more homogeneous products. That technology was originally developed in the context of antibody-drug conjugates, but the Secarna collaboration demonstrates why such a platform may have utility across multiple antibody-guided modalities.

“Achieving this milestone in our collaboration with Secarna in less than a year demonstrates that our conjugation technology powered by our proprietary click chemistry can be applied efficiently within partnerships beyond our company’s primary focus areas in solid tumors,” said Christoph Erkel, Ph.D., Chief Scientific Officer of VERAXA. “We look forward to continuing our collaboration with Secarna, a leading innovator in oligonucleotide-based therapeutics and unlocking the breadth of opportunities in this emerging drug class.”

For more information, visit the company’s website at www.Veraxa.com.

NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA